OPRX-106 for mild-to-moderate UC performs well in phase IIa trial
Oral administration of the nonabsorbable OPRX-106 shows potential in the treatment of mild-to-moderate ulcerative colitis (UC), delivering favourable anti-inflammatory immune modulation without concurrent immune suppression, according to the results of a phase IIa trial.